FDA rejects oral treatment for type 1 diabetes


Proposed oral therapy for type 1 diabetes in adults has been rejected in the United States.

The rejection of what would have been the first oral treatment of type 1 diabetes in the United States is a serious setback for Lexicon Pharmaceuticals Inc., a small Houston-based suburban company, which is currently marketing a product and is suffering from losses. Nearly $ 1.5 billion As of December 31, Lexicon is developing the treatment, called Zynquista, in collaboration with the French pharmaceutical giant Sanofi.


Source link